Alexion Pharma (ALXN) Tops Q4 EPS by 11c, Offers FY Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q4 EPS of $2.71, $0.11 better than the analyst estimate of $2.60. Revenue for the quarter came in at $1.38 billion versus the consensus estimate of $1.31 billion.

GUIDANCE:

Alexion Pharma sees FY2020 EPS of $10.65-$10.85, versus the consensus of $11.37. Alexion Pharma sees FY2020 revenue of $5.5-5.56 billion, versus the consensus of $5.64 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
• Home Depot beats estimates, reaffirms fiscal 2026 guidance